Plain-English translation of NCT07571200 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a follow-up study for people who have already completed an earlier ALS treatment trial. If you qualify, you'll continue receiving —a medication injected into the fluid around your spinal cord—to see how safe it is and how well you tolerate it over a long period. The goal is to gather more information about this experimental treatment's long-term effects in people with ALS.
After early testing shows a new treatment might be promising, researchers need to watch patients over many months to make sure the medication remains safe and doesn't cause unexpected problems. This study extends that watchful period so doctors can better understand the long-term risks and benefits.
You likely qualify if…
You likely don't qualify if…
You will receive spinal injections of the medication at regular clinic visits for at least 96 weeks (nearly 2 years). You'll have check-ins with your medical team to monitor how you're doing and watch for any side effects. If at any point your doctor thinks continuing is unsafe, they can stop your participation to protect your health.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Belgium
Canada
Germany